Making Informed Decisions In Your Oncology Study: Understanding Biomarkers

Every step in a successful oncology study requires carefully thought-out decisions. Biomarkers provide a rapid way to inform these choices by offering objective data across the entire spectrum of cancer care. Drawn from blood, plasma, or serum, circulating biomarkers serve as minimally invasive tools that generate standardized and reproducible results. They help track tumor burden, identify early signs of metastasis, and reduce patient radiation exposure by minimizing the need for repeated imaging. In rapidly evolving fields like immuno-oncology, combining multiple signals into a single composite biomarker algorithm allows researchers to better predict how specific patient groups will respond to treatment.

While these tools offer immense value, developers must address critical operational factors before implementing them in early-phase clinical trials. Teams need to clearly define the biomarker's role, select appropriate testing laboratories, and establish clear guidelines for sample collection and processing. Managing logistics effectively helps minimize turnaround times and control variable assay costs. By proactively building a fit-for-purpose strategy, sponsors ensure high data integrity, satisfy regulatory frameworks, and successfully support dose selection for accelerated clinical development.